Hikal Ltd Q3 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/kvacc5ojiqjuispoxc0mpyap.pdf

Key Takeaways


Pharma: The Margin Recovery

Hiremath: "A few years ago, this pipeline was a few products, then it became 5 to 6 products. Now we're talking of 13 to 14 products. As we go forward, the number of projects during -between Phase II B and Phase III will be at any given time, we're targeting to increase this number well beyond 14."

Crop Protection: Volume Up, Value Down


Animal Health: The Next Leg

Swadi: "When we look at validation for the innovator customer, what we do is we basically are validating the product, right, for all customers. So, when the validation happens, it's not only for one customer, it's for all customers because we're scaling up the product and putting it into commercial and getting all the data for filing."

CDMO Pipeline & Growth Ambition

Hiremath: "I think we are anticipating a growth in the next 3 to 5 years of high teens per year-on-year CAGR if you were to project ourselves out and we were sitting together here in FY '28, 3-4 years from now, and we have to review where the business was in FY '24 and where we are stepwise, we'll get there."

Margins, Capex & Capital Allocation

Hiremath: "Our aim is to cross the 20% barrier, which we were historically doing about 2, 3 years ago. So, our target is to cross that first and go beyond that also, yes."

Competitive Positioning & Unanswered Questions

Swadi: "But look, it's a volatile situation, right? We don't know how it's going to pan out, whether it's a negotiating tactic with the new administration."

Guidance & Commitments

CommitmentSpecificsTimeline
Animal Health commercializationFirst commercial revenues from some products as registrations come throughFY26 (toward end of FY26 for broader commercial revenue)
Animal Health scale targetIndependent division with business in excess of INR400+ crores5 years
Pharma CDMO launchesTwo products very close to launch; commercial supply of NCE validation quantities beginsEnd-FY26 for two products; end-CY26/early-FY27 for NCE commercial supply
CDMO revenue mixCDMO to overtake generics, targeting 60-40 splitNo date given
Overall EBITDA marginCross 20% barrier, then go beyondNo date given
Company revenue CAGRMid- to high teens year-on-year CAGR, on a base of INR2,000 crores3 to 5 years
Crop Protection pipeline8+ active projects under filing or launch, none commodity; drive growthFY27 onwards
FY26 capexINR150–200 crores (30–40% replacement, balance growth/debottlenecking)FY26
Panoli facility ramp-upNew multipurpose facility capitalized; ramp-up over next 2–3 years2–3 years
Crop Protection industry stabilizationGlobal crop protection industry expected to stabilizeNext 2–3 quarters

Key Metrics

MetricQ3 FY25
Revenue₹448 cr, +3% YoY on a 9M basis
EBITDA₹72 cr, +11% YoY
EBITDA margin16.1%, +11% YoY EBITDA growth on flat revenue
Pharma revenue₹293 cr, +7.1% YoY on a 9M basis
Pharma EBIT margin11.3%, +450 bps YoY; 9M EBIT margin improved from 5% to 10%
Crop Protection revenue₹154 cr, -3.3% YoY on a 9M basis
Crop Protection EBIT margin9%
Operating cash flow₹102 cr positive, 9M YoY increase
Gross debt₹731 cr as of December 2024
Capex₹140–150 cr guided for FY25; ₹150–200 cr planned annually thereafter
R&D spend4.5–5% of revenue
Pharma CDMO revenue share~40% on a 9M basis
Crop Protection CDMO revenue share~70% historically
Crop Protection volume growth41% on a 9M basis
Pharma volume growth3.7% on a 9M basis